|Articles|October 15, 2021
GeneTherapyLive’s Weekly Rewind – October 15, 2021
Author(s)GeneTherapyLive Staff
Review top news and interview highlights from the week ending October 15, 2021.
Advertisement
Welcome to GeneTherapyLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. Natural Killer Cell Therapy Well Tolerated in Solid Tumors
Thorsten Graef, MD, PhD, chief medical officer, Acepodia, discussed data on ACE1702 presented at ESMO 2021. He touched on next steps for the therapy and compared it to other natural killer cell therapies.
2. AlloCAR T Programs Halted Following Chromosomal Abnormality
The FDA has placed all of Allogene Therapeutics’ AlloCAR T trials on clinical hold after a chromosomal abnormality was observed in a patient dosed with ALLO-501A in the ALPHA2 trial (NCT04416984). These programs span tumor types, with phase 1 studies assessing the therapies in hematologic malignancies, solid tumors, and as a lymphodepletion agent.
3. Advantages of mRNA-Based Gene Therapies
Jake Becraft, PhD, chief executive officer and cofounder, Strand Therapeutics, discussed the company’s technology and focus on mRNA therapies. He explained how Strand’s platform works to create these therapies and the ease of manufacturing and delivering such therapies.
4. CAR T-Cell Therapy From CRISPR Therapeutics Efficacious in CD19+ B-Cell Malignancies
CTX110 seems to be well-tolerated and efficacious in patients with relapsed or refractory CD19+ B-cell malignancies, according to updated data from the phase 1 CARBON trial (NCT04035434) announced by CRISPR Therapeutics.
5. TCR-T Cell Therapy Cleared for Phase 1/2 Study in Acute Myeloid Leukemia
The FDA has accepted Intellia Therapeutics’ investigational new drug application for NTLA-5001, an investigational CRISPR/Cas9 T cell receptor (TCR)-T cell therapy for the potential treatment of acute myeloid leukemia.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 10, 2025
September 10th 2025
- Trends in RNA Therapeutic Research
September 8th 2025
Advertisement
Advertisement
Trending on CGTlive®
1
Patients With DMD Treated With Avidity Biosciences’ Antibody Oligonucleotide Conjugate Del-Zota Show Functional Improvements
2
Around the Helix: Cell and Gene Therapy Company Updates – September 10, 2025
3
Patients Treated With REGENXBIO's MPS II Gene Therapy RGX-121 Sustain 82% Median Reduction in CSF HS D2S6 Levels Through 1 Year
4